Abstract The process of metastasis formation in cancer is not completely understood and is the main reason cancer therapies fail. Previously, we showed that dual liposomes simultaneously containing the hemostatic inhibitor, dipyridamole and the anticancer drug, perifosine potently inhibited metastasis, causing a 90% reduction in the number of lung metastases in a murine experimental metastasis model. To gain deeper insight into the mechanisms leading to the inhibition of metastasis by these dual liposomes, in the present study, the development of metastases by MT3 breast cancer cells in a mouse xenograft model was analyzed in more detail with regard to tumor cell settlement and metastatic growth. We found that the development of lung metastases by MT3 tumor cells is essentially dependent on the formation of fibrin clots as a precondition for the pulmonary arrest of tumor cells and the subsequent intravascular expansion of micrometastases before their invasion into the surrounding tissue.
Introduction
About 3.2 million new patients are diagnosed with cancer in the European Union every year, 30% of whom already have detectable metastases. Although cancer metastasis is still the major cause of cancer therapy failure and the reason for the high mortality rate in cancer patients, the underlying processes leading to the formation of metastases are not completely understood.
Metastasis is a complex multistep process. It involves the detachment of tumor cells from the primary tumor, their penetration into blood vessels, as well as their entry into the circulation and adhesion to the endothelium, allowing tumor cell extravasation into the surrounding tissue and colonization at secondary sites [1] [2] [3] [4] . During circulation in the blood stream and resettlement at distant sites, extensive interactions between tumor cells and endothelial cells and/or blood components like platelets occur [5] [6] [7] [8] . These interactions can be mediated by specific ligands, like Sialyl-Lewis X or A that are expressed on the surface of tumor cells and P-and E-selectins found on platelets and endothelial cells respectively [7, 9, 10] .
The important role of platelets in the process of metastasis is well known since Trousseau [11] first described the close correlation between cancer and thromboembolic diseases. Several investigations have demonstrated the significant role platelets play in metastasis by forming aggregates with circulating tumor cells, promoting tumor cell adhesion, and enhancing cancer development and progression [3, [7] [8] [9] . Tumor cell-induced platelet aggregation results in the development of tumor cell-platelet microemboli [3, 5, 7, 12, 13] . These microemboli protect tumor cells from attack by natural killer cells [3, 7, 13] , leading to an enhanced arrest of tumor cellplatelet aggregates in small blood capillaries and facilitating tumor cell invasion into the surrounding tissue [3, 5] .
Subsequently, single tumor cells migrate into the extracellular tissue [3, 14] , or tumor growth begins inside the blood vessel until micrometastases invade the surrounding tissue [15] .
Two general therapeutic approaches exist to attack tumor cells migrating in the blood stream; the first is to prevent tumor cells from interacting with the endothelial membrane [16] [17] [18] , and the second is to inhibit formation of aggregates between platelets and tumor cells [6, 9, 19, 20] . Efforts to prevent tumor cells from adhering to endothelial cells have mostly focussed on a competitive blockade of the E-selectin receptor on vascular endothelial cells [21, 22] . In recent studies, we used liposomes bearing Sialyl-Lewis X -ligands; these prevented the binding of different tumor cell lines to endothelial cells in vitro, but failed in vivo [23] . A detailed investigation revealed that the presence of ligand-modified liposomes facilitates the assembly of tumor cell-platelet aggregates, which might have enhanced the formation of lung metastases [24] .
Borsig et al. [7, 25] showed that aggregate formation between platelets and tumor cells in L-and P-selectindeficient mice, and the subsequent number of lung metastases in the mice was significantly reduced. They also showed that the formation of complexes between tumor cells and platelets is primarily modulated by P-selectin, and that deficiency in P-selectin expression significantly reduced metastasis [7, 25] . Thus, preventing or inhibiting aggregate development can be regarded as a new approach to inhibit metastasis [26] .
We developed dual liposomes (D/O-L), which simultaneously contain the cancerostatic drug perifosine (OPP) and the hemostatic inhibitor dipyridamole (DIP). These D/ O-L completely abolished aggregate formation between tumor cells and platelets in vitro and significantly reduced the formation of lung metastases in mice by 90% in a previous study [26] .
Despite the convincing therapeutic effect observed in this experimental model of metastasis, how the tumor cells settled and the metastases grew in the lungs of the mice after an intravenous (i.v.) injection of MT3 breast cancer cells remained unclear. Additionally, we wanted to characterize the mechanism of action responsible for the D/O-L anti-metastatic effect. Our results show that metastasis in the MT3 breast cancer model involves intravasal fibrin clot formation within the capillary system of mouse lungs. This is apparently an initial and essential step for the development of metastases, because preventing fibrin clot formation with a single i.v. injection of D/O-L significantly reduced the number of pulmonary metastases.
Materials and methods

Materials
Cell culture material was obtained from Life Technologies (Karlsruhe, Germany) or Biochrom (Berlin, Germany). Collagen, cuvettes, magnetic stirrer and NaCl for aggregometer measurements were purchased from Chrono-Log. Dicetylphosphate and cholesterol were obtained from Serva (Heidelberg, Germany), DIP from Sigma-Aldrich (Steinheim, Germany). N-Methyl-(polyethyleneglycyl) 2000 -1,2-distearyl-s,n-glycero-3-phosphatidylethanolamine was purchased from Lipomed (Arlesheim, Switzerland). OPP was a generous gift from Dr. Hilgard (ASTA Medica, Frankfurt) and phosphatidylcholine (PC) from Lipoid (Ludwigshafen). Solvents and high performance thin layer chromatography (HPTLC) plates were purchased from Merck (Darmstadt, Germany).
Methods
Preparation and characterization of vesicles
Dual liposomes and Control-L (Con-L) were prepared as described previously [26] . Briefly, vesicles were prepared by lipid film/hydration method in combination with extrusion through polycarbonate filters of 400 nm pore size. Non-encapsulated DIP was removed by size exclusion chromatography using Sephadex-G50. Vesicle size was determined by photon correlation spectroscopy using a Coulter Counter N5 (Coulter Electronics, Inc., Hialeah, USA). Final concentrations of liposomal PC and OPP were determined by HPTLC. DIP was determined by fluorescence measurement at 415 (excitation) and 500 nm (emission) wave length as described previously [26] .
Cell culture
Human MT3 breast cancer cells [27] were cultured to sub confluence in RPMI medium supplemented with 10% fetal calf serum and 2 mol/ml L-glutamine, at 37°C, 90% humidity and 5% CO 2 . The cells were detached by a brief exposure to trypsin solution (0.25% trypsin, 0.53 mmol EDTA), spun down at 200 g -1 for 4 min, resuspended in medium and counted in a Neubauer chamber for a dilution as indicated.
In vitro experiments
Platelet aggregation: Platelet aggregation was determined with an impedance aggregometer (Chrono-Log) as described previously [26] . For that purpose, human platelets in plasma were mixed with 900 nmol total lipid of D/O-L or Con-L, activated with 5 ng/ml collagen and the aggregation was measured at 37°C. The higher the platelets are activated, the more platelets aggregate in layers around the surface of the electrodes. These platelet layers result in an increase in the electrical resistance between the two electrodes [28] . The maximal aggregation value (amplitude given in ohm) was obtained after 20 min, when a plateau phase was reached.
Complex formation of platelets and tumor cells: Aggregate formation of MT3 tumor cells in the presence of platelets was performed as described previously [26] . Briefly, platelets and fluorescently labeled MT3 cells were mixed with D/O-L or Con-L and thrombin. The formation of tumor cell aggregates was analyzed after 20 min incubation by microscopic quantification as described previously [26] . The results present the mean number of MT3 cell complexes with at least five cells counted in two representative areas with a total of 80-160 tumor cells in each area. Each experiment was performed in duplicate for four different platelet populations.
In vivo mouse experiments
All animal experiments were performed according to the German Animal Protection Law and by approval of the local responsible authorities.
Female NMRI:nu/nu mice and Crl:Balb/c mice were obtained from Taconic Europe, Denmark. The animals were held under pathogen-free conditions in individually ventilated cages under standardized environmental conditions (22°C room temperature, 50 ± 10% relative humidity, 12 h light-dark rhythm). They received autoclaved food and bedding (Ssniff, Soest, Germany) and acidified (pH 4.0) drinking water ad libitum.
Determination of platelet and leukocyte number and platelet aggregation Each of four female NMRI:nu/nu mice received i.v. 5 9 10 6 human MT3 breast cancer cells in 400 ll PBS or D/O-L in 100 ll PBS (100 nmol total lipid). Control mice only received 400 ll PBS. At the indicated time points between 0.5 h and 10 days, tail vein blood was taken and immediately mixed with sodium citrate in a volume ratio of 9:1.
Platelet and leukocyte count: The number of platelets and leukocytes in the mouse blood after tumor cell injection was measured with a cell counter device (Coulter counter).
Platelet aggregation ex vivo: A volume of 180 ll tail vein blood of each mouse was mixed with 720 ll 0.9% sodium chloride. Platelet aggregation was determined with an impedance aggregometer (Chrono-Log) as described earlier. Aggregation was measured for 20 min at 37°C after activation with 5 ng/ml collagen.
Analysis of tumor cell settlement in mouse lungs
Each of four female NMRI:nu/nu mice per experimental group was i.v. injected with 5 9 10 6 MT3 breast cancer cells. Two out of these four mice were additionally treated with 100 nmol total lipid of D/O-L 6 h before tumor cell injection. Mice were killed at the indicated time points and the lungs were fixed in 5% formalin solution.
Paraffin embedding and hematoxylin/eosin staining of lung sections: Half of the lungs embedded in paraffin were cut into slices with a thickness of 2-3 lm using a rotation microtome and every third section was stained with hematoxylin/eosin. The lung sections were covered with synthetic mounting media (Bio Mount; Bio Optica) and analyzed with a fluorescence microscope BX 51 (Olympus). Pictures were taken at 20-or 40-fold magnification.
Detection of tumor cells and fibrin(ogen) in paraffin lung sections: For fibrin(ogen) detection, paraffin lung sections were deparaffinized with pepsin solution (10 min at 37°C) and incubated with a polyclonal rabbit anti-mouse fibrinogen antibody (Oxford Biomedical Research) diluted 1:4,000. Then, the sections were incubated with a biotinylated goat anti-rabbit antibody (Biocare) for 45 min at room temperature (RT), followed by an incubation with peroxidase-labeled streptavidine (Zytochem Plus Kit; Zytomed Systems) for 10 min (RT). The visualization was done with the substrate AEC (3-component-system; Zytomed Systems) after 10 min incubation (RT). Finally, sections were stained in hematoxylin (Richard Allen) and embedded in Aquatex (Merck).
For detection of tumor cells, the paraffin slides were deparaffinized by heat-induced antigen-demasking with citrate buffer (pH 6) for 5 min at 120°C. Human MT3 tumor cells were stained using the monoclonal Pan Cytokeratin antibody mouse anti-human CK AE1/3 (Zymed laboratories) in a 1:400 dilution (45 min incubation).
Spontaneous metastasis in vivo
Female Crl:Balb/c mice received 1 9 10 4 murine 4T1 breast cancer cells transplanted into the mammary fad pad. Primary tumor growth was observed over the whole experimental period. Mice were treated i.v. with 100 ll liposome suspension containing 100 nmol total lipid of D/O-L 6 h before tumor cell inoculation and then daily for 2 weeks. Control mice were treated with PBS. In additional control groups, mice received 100 ll liposomes containing one or none of the drugs, or the free drugs DIP and OPP together, all in drug concentration corresponding to that in D/O-L. Mice were killed after 30 days and the number of metastases in mouse lungs was determined. This experiment was performed twice with a total of 16 mice per experimental group.
Statistical evaluation
Statistical comparisons of the data were performed with the unpaired Student's t-test (two populations). Differences were considered to be significant at P \ 0.05.
Results
We first injected mice with a single bolus of human MT3 tumor cells to determine the effect on the number and the physiological properties of mouse platelets. We found that the i.v. injection of MT3 tumor cells reduced the number of platelets by 40% as soon as 30 min after the injection. The decreased platelet count persisted for more than 1 day. After 3 days, the platelet count recovered and was comparable to that of controls (Fig. 1) . The same effect was observed for leukocytes, with a 50% reduction in the number of white blood cells (Fig. 1) .
We prepared D/O-L that simultaneously contain OPP and DIP. As a control, liposomes containing no drugs but with the same lipid composition were prepared (Con-L).
When human platelets were mixed with 900 nmol of D/O-L or Con-L, and activated with 5 ng/ml collagen at 37°C, the D/O-L significantly reduced the aggregation of human platelets in vitro by 60%, whereas empty Con-L had no affect on platelet aggregation (Fig. 2a) . These data are consistent with results obtained after i.v. injection of 100 nmol D/O-L into mice. The ex vivo aggregation measurement in mouse blood showed that the ability of the mouse platelets to aggregate was reduced by 90% 6 h after liposome injection (Fig. 2b) .
Next, we determined whether complex formation between MT3 breast cancer cells and activated platelets was affected by liposomes (Fig. 3) . The mean number of MT3 tumor cell complexes (consisting of five or more tumor cells) was significantly increased from 2.3 ± 2.0 to 5.9 ± 3.2 aggregates in the presence of thrombin-activated platelets. Complex formation was completely abolished by D/O-L. In the presence of D/O-L, the mean number of MT3 tumor cell aggregates was 1.8 ± 1.3, which is comparable to the mean number of complexes observed in the presence of non-activated platelets. The Con-L had no effect on the number of the complexes formed (Fig. 3) . Additionally, the size of the tumor cell aggregates, defined as the number of complexbound tumor cells in each microscopic field was determined. The number of complex-bound tumor cells was significantly elevated from 12.8 ± 10.6 for non-activated platelets to 52.9 ± 22.7 after thrombin activation. In the presence of non-activated platelets, a minimum of 0 and maximum of 33 aggregate-bound tumor cells per microscopic field were counted. In contrast, a minimum of 27 and a maximum of 103 aggregate-bound tumor cells per microscopic field were detected in the presence of thrombin-activated platelets. In the presence of D/O-L, the mean number of aggregate-bound tumor cells was only 12.1 ± 9.5 per microscopic graph, with minimum and maximum values of bound tumor cells between 0 and 32 respectively.
The ability of murine platelets to aggregate was determined after i.v. injection of MT3 tumor cells into mice. Figure 4a shows that collagen-activated platelets from tumor cell-free control mice resulted in a mean amplitude of 18 ohm measured with an impedance aggregometer ex vivo. Tumor cell inoculation led to a 40% reduction in mouse platelet aggregation if blood was collected 3-6 h after tumor cell injection. The lowest aggregation values were observed after 6 h. When mice were treated with D/O-L 6 h before MT3 tumor cell injection, the ability of platelets to aggregate was reduced by 80% in comparison with tumor cell-injected mice with a mean amplitude of 2 ohm (Fig. 4b) .
Additionally, the recalcification time (blood clotting time) of mouse blood after i.v. inoculation of MT3 breast cancer cells into mice was determined ex vivo. The blood clotting time was significantly prolonged by 45% 30 min To characterize the mode of tumor cell settlement and the formation of metastases in the mouse lung in the MT3 breast cancer xenograft model, mice were killed at different time points after injection of MT3 breast cancer cells into the lateral tail vein, and lung sections were prepared.
Microscopic analysis of the lungs showed that the lungs of control mice exhibited no alteration in hemostatic status and no fibrin clots were observed in the blood vessels (Fig. 5a ). In contrast, fibrin clots were found in the lungs of mice injected with tumor cells within 30 min after injection. These clots occluded the entire blood vessel and entrapped single tumor cells (Fig. 5b) . The presence of fibrin(ogen) and tumor cells was confirmed by immunohistological staining with rabbit anti-mouse fibrinogen antibody (Fig. 3c) and mouse anti-human CK AE1/3 antibody (Fig. 5d) respectively. Fibrin clots that did not contain tumor cells disappeared after 6 h.
On day 5, intravasal growing micrometastases were found, with some of the tumor cells in a mitotic state (Fig. 5e) . Fibrin-staining of the lung sections confirmed that the micrometastases were still infiltrated with (Fig. 5e ) and surrounded by (Fig. 5f ) fibrin. Large micrometastases filled the inner vessel spaces, destroying the endothelial lining and invading the surrounding tissue (Fig. 5g) . In our study, the tumor cells were always trapped in fibrin clots, Using D/O-L in four independent experiments in the experimental MT3 breast cancer metastasis model, a 90% reduction in the number of pulmonary and a 60% reduction in extrapulmonary metastases was obtained with a single D/O-L treatment 6 h before tumor cell inoculation [26] .
Additionally, a spontaneous model for breast cancer metastasis was used in this study to prove the anti-metastatic effect of the D/O-L in a clinically more relevant model. Therefore, murine 4T1 breast cancer cells were transplanted into the mammary fad pad of mice. After 2 weeks the primary mamma tumors had sizes of around 0.23 cm 3 when tumor cells started to metastasize to the lungs (data not shown). We found that the treatment of mice with 100 nmol total lipid of D/O-L 6 h before tumor cell inoculation and then daily for 2 weeks significantly reduced the mean number of pulmonary metastasis by 65% in comparison to the control and to drug-free Con-L (Fig. 6) . The combination of the free drugs dipyridamole and OPP together also reduced the mean number of metastases significantly by 33%, although the liposomal encapsulated drugs (D/O-L) were significantly better than the free drugs. OPP-L, DIP-L and Con-L did not reduce the number of metastases formed in mouse lungs (Fig. 6 ).
Discussion
The objective of this study was to investigate the mechanism of the anti-metastatic effect of D/O-L containing the hemostatic inhibitor, dipyridamole and the cytotoxic drug perifosine (OPP), in an experimental model of metastasis. Human MT3 breast cancer cells formed distinct metastatic foci, mostly in the lungs, after a single bolus injection into the mouse tail vein.
The direct inoculation of tumor cells into the circulation does not completely mimic the metastatic process, since it bypasses the first steps in metastasis, e.g., the detachment of single tumor cells from the primary tumor [29, 30] . On the other hand, an experimental metastasis model like this is suitable for investigating therapeutic mechanisms of action against circulating tumor cells, because the number of tumor cells in the circulation at a defined time point is standardized [29] . There are several hypotheses regarding how tumor cells interact with blood cells, attach to the endothelium, and migrate to the extra-cellular matrix to form metastases. Several studies described the ligand-based adhesion of single tumor cells to the endothelial membrane as an essential and initial step for tumor cell arrest [5, 16, 31] . Saiki et al. [16] suggested that the tumor cell may roll along the endothelium before it becomes tightly bound to the surface and extravasates into the adjacent tissue. Other studies led to the proposal that close interactions between circulating tumor cells and platelets are an essential step during metastasis [7, 8, 12, 32] . The accumulation of such tumor cell-platelet microemboli in narrow capillaries can facilitate tumor cell invasion into the surrounding tissue [2, 5] .
Several studies showed that circulating tumor cells could cause an activation and aggregation of platelets [3, 33, 34] . Our data also suggest that platelets play a direct role during development of micrometastases in the MT3 model, because the blood clotting time was found to be significantly longer and platelet aggregation was significantly impaired ex vivo after MT3 breast cancer cell inoculation into nude mice. This might originate, in part, from the fact that platelets have already been activated to some extent by circulating tumor cells. These activated platelets are not able to fully respond to an additional activator like collagen used to activate platelets during aggregometer measurements (Fig. 4) . On the other hand, the number of platelets in mouse blood was reduced immediately after injection of the tumor cells, as shown in Fig. 1 .
A similar effect was found 6 h after i.v. treatment of mice with D/O-L. There we found again a 90% reduction Breast Cancer Res Treat (2010) 121: 13-22 19 in the aggregability of the mouse blood platelets by ex vivo aggregometer measurements (Fig. 2b) . Several studies showed that an impaired platelet aggregation or a reduced platelet number results in the reduction of metastasis [35] . Our data suggest a direct role of platelets in metastasis in the MT3 model, because the inhibition of platelet aggregation by the dual D/O-L shown here, is accompanied by a significant reduction in the formation of pulmonary metastases seen after D/O-L treatment of mice. Muschel's group conducted comparable studies on tumor cell-platelet interactions and metastasis formation. These investigators suggested that the initial proliferation of tumor cells proceeds inside blood vessels [15] . They proposed a modified model of the development of pulmonary metastases, which includes the following steps: (1) ligand-mediated attachment of tumor cells to the lung endothelial membrane; (2) apoptosis of the majority of the attached tumor cells; (3) intravascular proliferation of the surviving tumor cells assisted by fibrin clots and platelets and (4) extravasation of micrometastatic foci into the surrounding tissue [36] . Additionally, they performed experiments using a spontaneous metastasis model and different cell types [15, 31] to confirm these data [36] .
Our findings are consistent with those of Muschel's group, except that in our model the settlement of tumor cells in the vasculature does not seem to be mediated through a direct interaction with the endothelial membrane. We found single MT3 cells in the center of fibrin clots, but never directly bound to the endothelial surface.
Moreover, our histological studies showed that massive fibrin clots were formed in pulmonary blood vessels directly after i.v. injection of MT3 breast cancer cells, and that these disappeared after 6 h. Only tumor cells entrapped in fibrin clots were stable for several days, probably because they enabled tumor cell survival and proliferation in a protected environment with easy access to oxygen and nutrients without the need for neo-angiogenesis, as well as shielding the tumor cells from shear forces.
In a previous study, we showed that co-incubation of platelets and tumor cells with D/O-L abolished complex formation in vitro, and inhibited metastasis in vivo [26] . The mechanism whereby the D/O-L reduced metastasis was now explained more in detail in the present study.
We demonstrated here that a single dose of D/O-L completely abolished the formation of pulmonary fibrin clots and subsequently significantly reduced the number of lung metastases. It was shown before that the fibrin clots protect the tumor cells from natural killer cell attack [35] . So, the prevention of fibrin clot formation by the D/ O-L might enable an easier access of immune cells to the tumor cells facilitating their elimination from the blood stream [35] that resulted in a reduced metastases formation.
It was also shown by the group of Muschel that murine 4T1 breast cancer cells metastasize as single cells to the mouse lungs in a spontaneous metastasis model [36] .
In the current study we used, additionally to the experimental MT3 breast cancer xenograft model, this clinically more relevant 4T1 breast cancer model for spontaneous metastasis, to verify the anti-metastatic effect of the D/O-L.
Therefore, murine 4T1 breast cancer cells were transplanted into the mammary fad pad of mice resulting in a primary mamma tumor that was shown to metastasize via the hematogeneous route to the lungs and later to other sites, like liver, bone and brain [37, 38] . The 4T1 model metastasizes effectively to sites affected in human breast cancer and therefore displays the metastatic characteristics similar to those observed in cancer patients. We found that a daily treatment of mice with D/O-L for 2 weeks significantly reduced the mean number of pulmonary metastases by 65% in comparison to the control and to drug-free Con-L (Fig. 6) . So, we could confirm the efficiency of the D/O-L in a clinically more relevant model for metastasis.
This study showed that the formation of fibrin clots and the subsequent development of intravascular micrometastases are important and essential steps in the formation of pulmonary metastases by MT3 tumor cells in the used experimental metastasis model. D/O-L containing dipyridamole and perifosine is a new drug formulation that potently inhibits metastasis, suggesting that it may be a promising novel drug for future developments.
